Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Innovation Pharmaceuticals Inc (EM) IPIX

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.


EXPM:IPIX - Post by User

Post by kaos12on Mar 04, 2019 11:43pm
133 Views
Post# 29441760

Good heavens!

Good heavens!Maybe today will get us some attention. Up 26%.  We’re expecting a deal folks, isn’t anyone paying attention?  Hopefully some of those who lost money in the past will have a second look. Many disappointments with Prurisol but Brilacidin could lead the way. Setting up in Ireland. Think about the tax effect. IMHO I think Leo is starting to put all the pieces together. Still, if I ever met the man personally I would call him a greedy a hole for his wages with a low penny stock. $450,000 US/ year is unbridled greed in my books. Hopefully he is about to make a few of us a few Benjamin’s. 
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities